STOCK TITAN
  1. Home
  2. Sec-filings
  3. NIVF
  4. [Form 4] NewGenIvf Group Ltd Insider Trading Activity

NewGenIvf (NIVF) gives CEO 272K options that vest now

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

NewGenIvf Group Ltd (NIVF) granted its Chairman & CEO, Siu Wing Fung Alfred, stock options for 272,140 Class B Ordinary Shares. The options have an exercise price of US$0.0001 per share, vest immediately upon grant, and expire on August 17, 2033. Following this award, the reporting person holds 345,787 stock options directly. The grant was made under the company’s 2024 Share Incentive Plan and an Employee Stock Option Agreement dated August 17, 2026.

Positive

  • None.

Negative

  • None.
Insider Siu Wing Fung Alfred
Role Chairman & CEO
Type Security Shares Price Value
Grant/Award Stock Options (Right to Buy) F1 272,140 $0.00 $0.00
Holdings After Transaction: Stock Options (Right to Buy) — 345,787 shares (Direct)
Footnotes (1)
  1. F1. Reflects the grant of stock options to acquire 272,140 Class B Ordinary Shares of the Issuer at an exercise price of US$0.0001 per share, made pursuant to the Issuer's 2024 Share Incentive Plan and the Employee Stock Option Agreement, dated August 17, 2026, between the Issuer and the Reporting Person (the "Option Agreement"). The options vest upon grant and expire on August 17, 2033 (Grant Date + 7 years), subject to earlier termination as provided in the Option Agreement and the Plan.
Options granted 272,140 shares Stock options to acquire Class B Ordinary Shares granted to Chairman & CEO
Exercise price US$0.0001 per share Exercise price for the 272,140 newly granted stock options
Underlying shares 272,140 shares Class B Ordinary Shares underlying the newly granted options
Total options after grant 345,787 shares Total stock options beneficially owned by the reporting person following the transaction
Expiration date August 17, 2033 Expiration of the stock options granted to the CEO
Stock Options (Right to Buy) financial
"The security reported is described as "Stock Options (Right to Buy)""
Class B Ordinary Shares financial
"Options to acquire 272,140 Class B Ordinary Shares of the Issuer"
Class B ordinary shares are a type of ownership stake in a company that typically come with different voting rights or privileges compared to other share classes. For investors, they represent a way to hold part of the company’s value and influence its decisions, often with fewer voting rights than Class A shares. Understanding these shares helps investors assess their level of control and potential returns within a company.
exercise price financial
"at an exercise price of US$0.0001 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
2024 Share Incentive Plan financial
"made pursuant to the Issuer's 2024 Share Incentive Plan"
vest upon grant financial
"The options vest upon grant and expire on August 17, 2033"

FAQ

What equity award did NewGenIvf Group Ltd (NIVF) grant to its CEO?
NewGenIvf Group Ltd granted its CEO stock options for 272,140 Class B Ordinary Shares. These options were awarded under the 2024 Share Incentive Plan and an Employee Stock Option Agreement dated August 17, 2026.

What is the exercise price of the new NIVF stock options granted to the CEO?
The new stock options carry an exercise price of US$0.0001 per share. This very low strike price effectively gives the CEO the right to acquire Class B Ordinary Shares at a nominal cost upon exercise.

When do the newly granted NIVF options to the CEO vest and expire?
The options vest upon grant and expire on August 17, 2033. They remain outstanding for up to seven years, subject to earlier termination under the Employee Stock Option Agreement and the 2024 Share Incentive Plan.

How many NIVF stock options does the CEO hold after this grant?
After this grant, the reporting person holds 345,787 stock options directly. This figure reflects the total derivative securities of this type reported as beneficially owned following the transaction.

Were the NIVF CEO’s new options granted under a specific compensation plan?
Yes. The options were granted under NewGenIvf Group Ltd’s 2024 Share Incentive Plan and an Employee Stock Option Agreement dated August 17, 2026, which together govern vesting, expiration, and potential early termination.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Siu Wing Fung Alfred
(Last)(First)(Middle)
C/O 1/F, PIER 2, CENTRAL
(Street)
HONG KONG
(City)(State)(Zip)
HONG KONG
(Country)		2. Issuer Name and Ticker or Trading Symbol
NewGenIvf Group Ltd [ NIVF ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Chairman & CEO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/17/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Options (Right to Buy)$0.000108/17/2026A272,140 (1)08/17/2033Class B Ordinary Shares272,140$0345,787D
Explanation of Responses:
1. Reflects the grant of stock options to acquire 272,140 Class B Ordinary Shares of the Issuer at an exercise price of US$0.0001 per share, made pursuant to the Issuer's 2024 Share Incentive Plan and the Employee Stock Option Agreement, dated August 17, 2026, between the Issuer and the Reporting Person (the "Option Agreement"). The options vest upon grant and expire on August 17, 2033 (Grant Date + 7 years), subject to earlier termination as provided in the Option Agreement and the Plan.
/s/ Wing Fung Alfred Siu08/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google